Abstract

This study describes the preparation and evaluation of two formulations, a hydrogel and a nanostructured system, containing ketorolac tromethamine as an anti-inflammatory agent for the local therapy against the inflammatory process derived from the surgical excision of Condyloma acuminata. Both formulations were physicochemically characterized. In vitro release profiles show that the nanoparticles release 92% ± 2.3 of the total ketorolac tromethamine encapsulated, while the chitosan gel releases 18.6% ± 0.2. The ex vivo permeation and distribution through human skin were also assayed and was observed how the main amount of ketorolac tromethamine is retained in the epidermis. In vivo studies were accomplished to evaluate the anti-inflammatory efficacy in mice which also involved the histological analysis to confirm the in vivo results. The nanoparticles present a significantly higher anti-inflammatory efficacy than chitosan gel. The tolerability of developed formulations was assessed by monitoring the biomechanical properties of the skin before and after application of both formulations. No statistical differences in trans-epidermal water loss and skin hydration with respect to the basal values were observed and the formulations exhibited higher anti-inflammatory activity compared to a reference ketotorlac tromethamine solution. Therefore, it can be concluded that both formulations can be proposed as outstanding candidates for offering a local anti-inflammatory therapeutical tool with potential clinical application.

Highlights

  • Transmitted infections (STIs) represent nowadays a significant public health problem [1]

  • Similar profiles were observed for both gels, indicating that the addition of ketorolac tromethamine (KT) in the swelling study

  • Two polymeric formulations loading KT were developed to address the pain associated with the ablation of anogenital warts in Condyloma acuminata

Read more

Summary

Introduction

Transmitted infections (STIs) represent nowadays a significant public health problem [1]. One of the most common STIs is the human papillomavirus (HPV) infection [2], being Condyloma acuminata (CA) its clinical manifestation [3]. More than 200 HPV strains have been sequenced, of which 40 are known to cause genital infections [2]. There are two types of HPV in terms of the oncogenic risk, of which the virus subtypes 6 and 11, Pharmaceutics 2021, 13, 1784. Pharmaceutics 2021, 13, 1784 are classified as of low oncogenic risk, and are those which are mainly responsible 90% of cases. It is noteworthy that subtypes 16 and 18 in contrast are deemed as high-risk strains, due to their oncogenic potential [4]. Children [6] and pregnant women can be affected [7]

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call